Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...

Survival rates in the United States are improving, a new report shows. In the annual report from the American ...

Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...

For the first time ever, the five-year survival rate for all cancers combined has reached 70 percent. While it's a moment to ...

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...

An annual report from the American Cancer Society shows that, for the first time, over 70% of Americans diagnosed with cancer ...

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who ...

The result is a record 18 million cancer survivors in the US right now, a number expected to grow between 300,000 and 500,000 annually over the next 10 years. In turn, a cancer diagnosis is often no ...

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...

The American Cancer Society today released its annual “Cancer Statistics, 2026” and “Cancer Facts & Figures 2026” report — the first national snapshot of this year’s cancer trends. Experts from City ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...